CLIP2 Antibody

What is CLIP2 protein and why is it significant in research?

CLIP2 (CAP-Gly domain containing linker protein 2) is a cytoskeletal protein that plays a crucial role in microtubule organization and cell division. In humans, the canonical protein has 1046 amino acid residues with a molecular mass of approximately 115.8 kDa . CLIP2 is primarily localized in the cytoplasm and is widely expressed across numerous tissue types . The protein's significance in research stems from its role in linking microtubules to dendritic lamellar body (DLB), a membranous organelle predominantly present in bulbous dendritic appendages of neurons linked by dendrodendritic gap junctions . This makes CLIP2 particularly relevant in neuroscience research, as it may operate in the control of brain-specific organelle translocations . CLIP2 is also known by several synonyms including CLIP-115, CYLN2, WBSCR3, WBSCR4, WSCR3, WSCR4, and Williams-Beuren syndrome chromosome region 3 .

Which applications are CLIP2 antibodies most commonly used for?

CLIP2 antibodies are utilized across multiple research applications, with Western Blot (WB) being the most widely validated and employed technique. According to comprehensive antibody validation data, the following applications are common for CLIP2 antibodies:

These applications have been validated with various cell lines and tissues, including RAW 264.7 cells, A549 cells, rat brain tissue, mouse brain tissue, and cerebellum tissue . The diversity of validated applications makes CLIP2 antibodies versatile tools for researching this protein across multiple experimental contexts.

How should I select the most appropriate CLIP2 antibody for my research?

Selecting the optimal CLIP2 antibody depends on several factors including your specific application, target species, and experimental design. Consider the following methodology:

• Application compatibility: First determine which application you need (WB, IHC, IF, IP, or ELISA) and verify that the antibody has been validated for that specific application . Some antibodies perform well in certain applications but poorly in others.

• Species reactivity: Confirm that the antibody reacts with your target species. Many CLIP2 antibodies react with human, mouse, and rat samples, but cross-reactivity varies between products .

• Epitope location: Consider the region of CLIP2 that the antibody recognizes. Some antibodies target the N-terminal region (aa 100-250) , while others target different domains. This is particularly important if you're studying specific isoforms or domains of CLIP2.

• Validation data: Review the validation data for each antibody candidate. Look for evidence of specificity, such as single bands at the expected molecular weight (~115 kDa) in Western blots or clear subcellular localization in IF images .

• Published literature: Check for citations of the antibody in published research, which can provide confidence in its performance for specific applications .

For highly sensitive applications or when studying specific CLIP2 isoforms, consider using multiple antibodies targeting different epitopes to validate your findings .

What are the optimal storage conditions for maintaining CLIP2 antibody activity?

Proper storage is critical for maintaining antibody efficacy over time. For CLIP2 antibodies, the following storage conditions are typically recommended:

• Temperature: Store at -20°C for long-term preservation . Some manufacturers may recommend storage at 4°C for short periods after initial use.

• Buffer composition: Most CLIP2 antibodies are stored in PBS with 0.02% sodium azide and 50% glycerol at pH 7.3 or similar buffers that enhance stability .

• Aliquoting: For antibodies stored at -20°C, aliquoting upon receipt is generally unnecessary but can help prevent freeze-thaw cycles that may degrade antibody quality .

• Handling: Before use, allow the antibody to equilibrate to room temperature and mix gently. Avoid repeated freezing and thawing.

• Shelf-life: Under recommended storage conditions, most CLIP2 antibodies remain stable for at least one year after shipment .

For specific products, always consult the manufacturer's instructions, as storage recommendations may vary slightly depending on formulation details and preservatives used.

How can I validate the specificity of a CLIP2 antibody for my experimental system?

Validating antibody specificity is crucial for reliable research outcomes. For CLIP2 antibodies, a multi-faceted validation approach is recommended:

• Positive and negative control samples: Use tissues or cell lines known to express high levels of CLIP2 (such as brain tissue, A549 cells) as positive controls, and compare with low-expressing or knockout models as negative controls .

• Multiple detection methods: Employ orthogonal techniques to verify CLIP2 expression, such as combining protein detection (Western blot) with RNA assessment (RT-PCR or RNA-seq).

• Blocking peptides: Use the immunizing peptide to block antibody binding in a parallel experiment. Specific signal should be abolished or significantly reduced .

• Knockout/knockdown validation: The gold standard for antibody validation is testing in CLIP2 knockout or knockdown models. Confirm that the signal is absent or significantly reduced in these models .

• Molecular weight verification: In Western blots, CLIP2 should appear at approximately 110-120 kDa . Multiple bands could indicate isoforms, degradation products, or non-specific binding.

• Cross-reactivity assessment: Test against related proteins, particularly CLIP1 (which shares structural similarities), to ensure specificity. In published data, CLIP2 showed significantly higher enrichment (134 spectral counts) compared to CLIP1 (only 13 counts) in co-immunoprecipitation experiments .

When publishing research using CLIP2 antibodies, documenting these validation steps strengthens the reliability of your findings.

What are the key considerations when using CLIP2 antibodies in co-immunoprecipitation experiments?

Co-immunoprecipitation (co-IP) with CLIP2 antibodies requires careful optimization to maintain protein interactions while ensuring specificity. Based on published protocols , the following methodological considerations are crucial:

• Antibody amount optimization: For CLIP2 co-IP, use 0.5-4.0 μg of antibody for every 1.0-3.0 mg of total protein lysate . Excessive antibody can increase non-specific binding, while insufficient amounts result in poor target capture.

• Lysis buffer selection: Use non-denaturing buffers that preserve protein-protein interactions. For CLIP2 interactions with microtubule-associated proteins, buffers containing 150 mM NaCl, 1% NP-40 or Triton X-100, and protease inhibitors have proven effective .

• Negative controls: Always include parallel IPs with non-immune IgG of the same species as the CLIP2 antibody. Analysis tools like Significance Analysis of Interactome (SAINT) can help distinguish specific interactions from background binding, with scores above 0.65 typically indicating significant enrichment .

• Cross-validation: Confirm interactions using reciprocal IPs where possible, pulling down with antibodies against suspected interacting partners and blotting for CLIP2 .

• Data analysis: For mass spectrometry-based interactome studies, use spectral count comparisons and statistical analysis. In published studies of CLIP2-CLASP2 interactions, CLIP2 averaged 134 spectral counts in CLASP2 IPs versus only 13 for the related protein CLIP1 .

This methodology has successfully identified novel CLIP2 interaction partners including CLASP2, which links CLIP2 to microtubule dynamics regulation in cellular processes .

How do I troubleshoot weak or non-specific signals when using CLIP2 antibodies in immunohistochemistry?

When encountering challenges with CLIP2 immunohistochemistry, systematic troubleshooting can improve results. Based on validated protocols , consider the following approach:

• Antigen retrieval optimization:

  • For CLIP2 IHC, heat-induced epitope retrieval (HIER) using TE buffer at pH 9.0 is often recommended

  • As an alternative, citrate buffer at pH 6.0 can be tested

  • Different retrieval times (10-30 minutes) should be evaluated if signal is weak

• Antibody dilution titration:

  • Test a range of dilutions around the recommended 1:400-1:1600 range

  • Prepare a dilution series and perform parallel staining to identify optimal concentration

• Fixation considerations:

  • Overfixation can mask epitopes; limit fixation in 4% formaldehyde to 24 hours

  • For frozen sections, post-fixation in acetone or 4% paraformaldehyde for 10 minutes is typically sufficient

• Blocking optimization:

  • Increase blocking time or concentration (5-10% normal serum)

  • Add 0.1-0.3% Triton X-100 for better antibody penetration in tissue sections

  • Use protein-free blocking buffers if background persists

• Detection system enhancement:

  • Switch to more sensitive detection systems (polymer-based vs. ABC method)

  • Amplification systems like tyramide signal amplification can enhance weak signals

• Positive control inclusion:

  • Always run parallel staining on tissues known to express CLIP2 (brain tissue is ideal)

  • Compare your results with published IHC images of CLIP2 staining patterns

For non-specific background, adding 0.1-0.3% Tween-20 to wash buffers and extending wash times between steps often improves results.

What is the significance of CLIP2 in disease models and how can antibodies help elucidate its role?

CLIP2 has been implicated in several disease states, making it an important research target. CLIP2 antibodies play crucial roles in investigating these disease associations:

• Neurodegenerative diseases:

  • CLIP2's role in microtubule organization makes it relevant in studying neurodegenerative conditions

  • Antibodies enable visualization of CLIP2 localization changes in disease models using immunofluorescence

  • Western blots with CLIP2 antibodies can detect altered expression levels or post-translational modifications in brain tissues from disease models

• Cancer research:

  • Dysregulation of CLIP2 has been implicated in cancer progression

  • IHC with CLIP2 antibodies can assess expression patterns across tumor tissues and correlate with clinical outcomes

  • CLIP2's potential roles in cell division and motility can be investigated using antibody-based techniques in cancer cell lines

• Williams-Beuren Syndrome:

  • CLIP2 (also known as WBSCR3/WBSCR4) is associated with Williams-Beuren syndrome chromosome region

  • Antibodies allow researchers to study how CLIP2 haploinsufficiency affects cellular phenotypes in this genetic disorder

  • Differential expression analysis between patient-derived and control cells can be performed using CLIP2 antibodies

• Experimental approaches:

  • Immunoprecipitation coupled with mass spectrometry can identify novel CLIP2 interacting partners in disease contexts

  • Chromatin immunoprecipitation (ChIP) can investigate potential transcriptional regulation of CLIP2 in disease states

  • Proximity ligation assays using CLIP2 antibodies can detect protein-protein interactions in situ in tissue samples

These applications demonstrate how CLIP2 antibodies facilitate mechanistic studies of CLIP2's involvement in pathological processes, potentially identifying new therapeutic targets.

What emerging techniques are enhancing the utility of CLIP2 antibodies in research?

Several innovative methodologies are expanding the applications of CLIP2 antibodies in cutting-edge research:

• Antibody-barcode eCLIP for RNA binding protein analysis:

  • This technique uses DNA-barcoded antibodies and proximity ligation to study RNA-binding proteins

  • The method addresses constraints of traditional eCLIP through on-bead proximity-based ligations

  • DNA barcodes enable multiplexed analysis, distinguishing different proteins within the same sample

  • This approach dramatically reduces input requirements and allows study of RNA-protein interactions with limited samples

• Machine learning-driven antibody design platforms:

  • Recent developments at Lawrence Livermore National Laboratory demonstrate how computational approaches can design novel antibodies

  • While initially applied to SARS-CoV-2 antibodies, similar principles could enhance CLIP2 antibody development

  • These platforms combine known antibody structures with machine learning algorithms to predict mutations that optimize binding

  • This computational-experimental iterative process could produce more specific CLIP2 antibodies for challenging applications

• TRACeR platform for targeted recognition:

  • The TRACeR-II platform represents a novel approach using a small helical bundle scaffold with a single loop for antigen recognition

  • This methodology could potentially be adapted for developing highly specific CLIP2 targeting agents

  • The platform enables rapid evolution across multiple targets and computational protein design for specific antigens

  • This approach might overcome limitations of traditional antibodies for certain applications

• Multiplexed protein interaction network analysis:

  • Spectrum Count Profile (SCP) visualization techniques help analyze complex protein interaction networks

  • This methodology has successfully identified CLIP2 interactions with proteins like CLASP2

  • The approach enables hierarchical analysis of raw spectral count data from interactome experiments

  • Such techniques provide deeper insights into CLIP2's functional role in cellular processes

These emerging techniques demonstrate the evolving landscape of antibody-based research tools that continue to expand our understanding of CLIP2 biology.

What are the optimal protocols for using CLIP2 antibodies in immunofluorescence studies?

For successful immunofluorescence (IF) with CLIP2 antibodies, the following optimized protocol is recommended based on validated experimental procedures :

• Sample preparation:

  • For cultured cells: Fix in 4% formaldehyde for 10-15 minutes at room temperature

  • Permeabilize using 0.2% Triton X-100 in PBS for 10 minutes

  • Block in 10% normal goat serum (or serum matching the secondary antibody host) for 1 hour at room temperature

• Primary antibody incubation:

  • Dilute CLIP2 antibody to 1:50-1:200 in blocking buffer

  • Incubate overnight at 4°C in a humidified chamber

  • For A549 cells, a 1:166 dilution has been validated with successful results

• Secondary antibody detection:

  • Wash 3× with PBS, 5 minutes each

  • Incubate with appropriate fluorophore-conjugated secondary antibody (e.g., Alexa Fluor 488-conjugated goat anti-rabbit IgG) at 1:500-1:1000 for 1 hour at room temperature

  • Include DAPI (1:1000) during secondary antibody incubation for nuclear counterstaining

• Mounting and imaging:

  • Mount with anti-fade mounting medium

  • Image using confocal or fluorescence microscopy with appropriate filters

  • CLIP2 typically shows cytoplasmic localization with emphasis on microtubule structures

For challenging samples, signal amplification systems or tyramide signal amplification (TSA) can enhance detection sensitivity while maintaining specificity.

How can I quantify CLIP2 expression levels in tissues or cells using antibody-based techniques?

Accurate quantification of CLIP2 expression requires appropriate techniques and controls. Here are methodological approaches for reliable quantification:

• Western blot quantification:

  • Use a dilution series of recombinant CLIP2 protein as a standard curve

  • Load equal amounts of total protein (verified by housekeeping proteins like GAPDH or β-actin)

  • Analyze band intensity using software like ImageJ, normalizing to loading controls

  • For optimal results, use CLIP2 antibodies at the recommended dilution of 1:5000-1:50000

• Immunohistochemistry quantification:

  • Use automated image analysis software (QuPath, ImageJ, etc.) to measure staining intensity

  • Implement H-score method: H-score = (% of cells with 1+ intensity × 1) + (% of cells with 2+ intensity × 2) + (% of cells with 3+ intensity × 3)

  • Always include internal controls and standard tissues with known CLIP2 expression

  • For accurate comparison between samples, process all tissues simultaneously using identical conditions

• ELISA-based quantification:

  • Develop a sandwich ELISA using two different CLIP2 antibodies targeting non-overlapping epitopes

  • Create a standard curve using purified recombinant CLIP2 protein

  • Optimize antibody concentrations (capture: 1-10 μg/ml; detection: 1:2000-1:10000)

  • Calculate protein concentration based on the standard curve

• Flow cytometry for cellular analysis:

  • Fix and permeabilize cells appropriately for intracellular staining

  • Use directly conjugated CLIP2 antibodies when available, or appropriate secondary antibodies

  • Quantify using mean fluorescence intensity (MFI) relative to isotype controls

  • Include positive control cell lines with known CLIP2 expression levels

For all quantification methods, biological replicates (n≥3) and technical replicates are essential for statistical validity, and appropriate statistical tests should be applied based on data distribution.

How should I design experiments to study CLIP2 interactions with other proteins using antibody-based approaches?

Investigating CLIP2 protein interactions requires careful experimental design. Based on successful research protocols , the following comprehensive approach is recommended:

• Co-immunoprecipitation strategy:

  • Forward and reverse Co-IP: Pull down with CLIP2 antibody and blot for suspected interactors, then perform the reciprocal experiment

  • Input controls: Always analyze 5-10% of the input sample alongside IP samples

  • Negative controls: Include IgG control IPs from the same species as the primary antibody

  • For CLIP2 IP, use 0.5-4.0 μg antibody per 1.0-3.0 mg of total protein lysate

• Proximity ligation assay (PLA):

  • Use antibodies from different species against CLIP2 and potential interacting partners

  • Optimize antibody dilutions independently before combining for PLA

  • Include appropriate controls: single antibody controls, known interacting and non-interacting protein pairs

  • Quantify PLA signals per cell across multiple fields for statistical analysis

• Mass spectrometry-based interactome analysis:

  • Implement SAINT (Significance Analysis of Interactome) methodology with a score cutoff of 0.65 to identify significant interactions

  • Create Spectrum Count Profiles (SCPs) to visualize and compare raw spectral count data across experiments

  • Perform hierarchical analysis of identified interactions based on spectral counts

  • Validate novel interactions using orthogonal methods

• Subcellular co-localization studies:

  • Use confocal microscopy with dual immunofluorescence staining for CLIP2 and potential interactors

  • Quantify co-localization using Pearson's or Mander's correlation coefficients

  • Implement super-resolution microscopy techniques for detailed interaction analysis

  • Include appropriate controls to confirm specificity of observed co-localization

These methods have successfully identified important CLIP2 interactions, such as its association with CLASP2, linking CLIP2 to key cellular processes including microtubule dynamics regulation .

What considerations are important when using CLIP2 antibodies in animal models for in vivo studies?

Using CLIP2 antibodies in animal models requires careful planning and consideration of several factors:

• Species cross-reactivity verification:

  • Confirm that your CLIP2 antibody recognizes the target species protein (mouse, rat, etc.)

  • Many commercial CLIP2 antibodies have been validated for reactivity with mouse and rat samples

  • Perform preliminary Western blots on tissue extracts from your animal model to verify specific binding

  • Note that CLIP2 gene orthologs have been reported in mouse, rat, bovine, frog, zebrafish, chimpanzee, and chicken species

• Tissue-specific expression patterns:

  • CLIP2 is widely expressed across tissues but shows particularly high expression in brain tissue

  • For brain studies, regional expression differences should be considered; cerebellum tissue shows strong CLIP2 expression

  • Use appropriate positive control tissues based on known expression patterns

• Immunohistochemistry optimization for animal tissues:

  • Fixation protocols may need adjustment for different species and tissue types

  • For mouse brain tissue, antigen retrieval with TE buffer at pH 9.0 is recommended

  • Antibody concentration typically needs optimization; start with 1:400-1:1600 dilution for IHC

• In vivo imaging considerations:

  • For intravital microscopy, consider using fluorescently conjugated CLIP2 antibodies

  • Test for potential immunogenicity if repeated administrations are planned

  • Optimize dose based on preliminary biodistribution studies

• Controls for in vivo experiments:

  • Include CLIP2 knockout or knockdown animals when possible as negative controls

  • Use isotype control antibodies to establish background signal levels

  • Consider developmental timing effects, as CLIP2 expression may vary during development

These methodological considerations have been applied in successful studies of CLIP2 function in rodent models, particularly in neurological research contexts.

How might emerging antibody technologies enhance CLIP2-related research and therapeutic development?

The future of CLIP2 antibody research will likely be transformed by several innovative technologies:

• Machine learning-based antibody design:

  • Similar to approaches used for SARS-CoV-2 antibodies, computational platforms can predict mutations to optimize CLIP2 antibody binding

  • These methods could produce antibodies with enhanced specificity for different CLIP2 isoforms or epitopes

  • The computational-experimental iterative process allows rapid refinement of antibody candidates

  • This approach could yield therapeutic antibodies targeting CLIP2-associated disease mechanisms

• Single-domain antibodies and nanobodies:

  • Smaller antibody formats may provide better access to sterically hindered epitopes of CLIP2

  • These formats show enhanced tissue penetration, potentially improving in vivo imaging

  • Their simplified structure facilitates genetic engineering for custom applications

  • They can be produced in bacterial systems, reducing production costs and timelines

• Antibody-drug conjugates (ADCs) for targeted therapy:

  • If CLIP2 dysregulation in certain cancers is confirmed, ADCs could enable targeted treatment

  • Coupling CLIP2 antibodies with cytotoxic agents would deliver therapy specifically to CLIP2-expressing cells

  • This approach could minimize off-target effects in therapeutic applications

  • Requires careful selection of antibodies with appropriate internalization properties

• Multi-specific antibodies:

  • Antibodies targeting both CLIP2 and interacting partners could provide insights into protein complexes

  • Bispecific formats could simultaneously target CLIP2 and therapeutic targets

  • These tools would enable functional studies of CLIP2 in specific cellular contexts

  • May reveal new mechanistic insights into CLIP2's role in disease processes

These emerging technologies promise to expand both basic research applications and potential therapeutic approaches targeting CLIP2-associated pathologies.

What role might CLIP2 antibodies play in understanding neurodegenerative diseases?

CLIP2 antibodies offer valuable tools for investigating neurodegenerative mechanisms, given CLIP2's roles in microtubule organization and potential involvement in neuronal function:

• Microtubule dynamics in neurodegenerative contexts:

  • CLIP2 appears enriched in the axonal growth cone and enables neuronal polarization by controlling microtubule stabilization

  • Antibodies can track CLIP2 distribution changes in neurodegenerative disease models

  • CLIP2's interaction with dendritic lamellar bodies may impact synaptic function

  • Quantitative analysis of CLIP2 expression and localization changes could identify early disease signatures

• Protein aggregation studies:

  • Co-localization studies using CLIP2 antibodies with disease-associated protein aggregates (tau, α-synuclein, etc.)

  • Potential involvement of CLIP2 in aggregate formation or clearance can be assessed

  • Changes in CLIP2 post-translational modifications during disease progression

• Williams-Beuren Syndrome connections:

  • CLIP2 (aka WBSCR3/WBSCR4) is associated with the Williams-Beuren syndrome chromosome region

  • Antibodies enable investigation of how CLIP2 haploinsufficiency affects neuronal development and function

  • This could provide insights into neurodevelopmental aspects of neurodegenerative vulnerability

• Therapeutic target validation:

  • If CLIP2 dysregulation contributes to neurodegeneration, antibody-based techniques can validate intervention points

  • Blocking or enhancing specific CLIP2 interactions might modulate disease progression

  • Monitoring CLIP2 as a biomarker for treatment response in preclinical models

The development of brain-penetrant antibody formats or imaging agents targeting CLIP2 could further enhance these research applications, potentially leading to diagnostic or therapeutic advances for neurodegenerative conditions.

What are the key considerations for validating and publishing research using CLIP2 antibodies?

When conducting and publishing research using CLIP2 antibodies, researchers should address several critical factors to ensure reliability and reproducibility:

• Comprehensive antibody reporting:

  • Include complete antibody information: manufacturer, catalog number, lot number, host species, clonality, and RRID (Research Resource Identifier)

  • Specify the target epitope when known (e.g., "antibody targeting amino acids 100-250")

  • Document all validation experiments performed specifically for your research context

• Control experiments:

  • Describe all positive and negative controls used to validate specificity

  • Include knockdown/knockout controls when available

  • Document cross-reactivity testing, particularly with closely related proteins like CLIP1

  • For each application, include appropriate technical controls (e.g., loading controls for Western blots)

• Protocol transparency:

  • Provide detailed methods including antibody dilutions, incubation times, buffer compositions

  • For quantitative analyses, explain normalization methods and statistical approaches

  • Share any troubleshooting steps or optimization procedures that proved critical

  • Consider providing raw data or images in supplementary materials or repositories

• Reproducibility considerations:

  • Validate key findings with multiple antibodies targeting different CLIP2 epitopes when possible

  • Complement antibody-based techniques with orthogonal methods (e.g., genetic approaches)

  • Report biological and technical replicate numbers clearly

  • Address batch effects or other sources of variability

• Application-specific validation:

  • For Western blot: Show full blots with molecular weight markers

  • For IHC/IF: Include magnification, scale bars, and detailed imaging parameters

  • For IP-MS: Provide SAINT scores or similar metrics for interaction significance

  • For multiplex applications: Document absence of cross-reactivity between detection systems